Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Second Quarter 2019 Financial Results
Revenue Grew 32% to $30.1 Million Genomic Test Volume Grew 26% to 9,663 Company Raises 2019 Full-Year Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for
Toggle Summary Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer
Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Keith Kennedy , the company’s current chief financial


Date Event Details
Summary Toggle Jul 30, 2019 2:00 PM PDT
Veracyte Second Quarter 2019 Financial Results Webcast
Summary Toggle Jun 6, 2019 9:00 AM EDT
Jefferies 2019 Global Healthcare Conference


Title Documents

Corporate Presentation August 2019